Metastatic Soft Tissue Sarcoma Clinical Trials

9 recruitingLast updated: June 17, 2026

There are 9 actively recruiting metastatic soft tissue sarcoma clinical trials across 5 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include Houston, Texas, United States, Toulouse, France, Aurora, Colorado, United States. Updated daily from ClinicalTrials.gov.


Metastatic Soft Tissue Sarcoma Trials at a Glance

9 actively recruiting trials for metastatic soft tissue sarcoma are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in Houston, Toulouse, and Aurora. Lead sponsors running metastatic soft tissue sarcoma studies include Institut Bergonié, M.D. Anderson Cancer Center, and Adcendo ApS.

Browse metastatic soft tissue sarcoma trials by phase

Treatments under study

About Metastatic Soft Tissue Sarcoma Clinical Trials

Looking for clinical trials for Metastatic Soft Tissue Sarcoma? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Soft Tissue Sarcoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Soft Tissue Sarcoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Metastatic Soft Tissue SarcomaMetastatic LeiomyosarcomaAdvanced Soft Tissue Sarcoma+5 more
National Cancer Institute (NCI)74 enrolled1 locationNCT06498648
Recruiting
Phase 1Phase 2

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Colorectal, CancerResectable SarcomaMetastatic Malignant Neoplasm in the Lung+3 more
Roswell Park Cancer Institute99 enrolled1 locationNCT03965234
Recruiting
Phase 1

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

Metastatic Soft Tissue Sarcoma
M.D. Anderson Cancer Center40 enrolled1 locationNCT06474676
Recruiting
Phase 1Phase 2

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

Metastatic Soft Tissue SarcomaUnresectable Soft Tissue Sarcoma
Adcendo ApS270 enrolled8 locationsNCT06797999
Recruiting
Phase 2

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Metastatic Soft Tissue SarcomaAdvanced Soft Tissue Sarcoma
University of Colorado, Denver65 enrolled1 locationNCT04028063
Recruiting
Phase 1

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Metastatic Soft Tissue Sarcoma
Washington University School of Medicine18 enrolled1 locationNCT06968988
Recruiting
Phase 2

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Metastatic Soft Tissue SarcomaAdvanced Soft Tissue Sarcoma
Institut Bergonié80 enrolled8 locationsNCT04874311
Recruiting
Phase 3

Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients

Metastatic Soft Tissue SarcomaAdvanced Soft Tissue Sarcoma
UNICANCER214 enrolled1 locationNCT04757337
Recruiting
Phase 1Phase 2

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Metastatic Soft Tissue SarcomaAdvanced Soft Tissue Sarcoma
Sarcoma Oncology Research Center, LLC250 enrolled1 locationNCT03138161